United Laboratories Advances Dual Pipeline with FDA Approval for TUL321 and China Approval for Dupilumab Biosimilar
核心洞察
United Laboratories (搜索)' wholly owned subsidiary Zhuhai United (搜索) received implied approval from China's National Medical Products Administration (搜索) for clinical trials of its dupilumab biosimilar injection targeting atopic dermatitis (搜索).
The company's TUL321 (搜索) capsules, a Class 1 innovative drug, obtained FDA approval for its Investigational New Drug application with IND number 180385.
Dupilumab is a fully human immunoglobulin G4 (搜索) monoclonal antibody designed for moderate-to-severe atopic dermatitis (搜索) patients inadequately controlled by topical therapies.
United Laboratories (搜索) (03933.HK) has achieved significant regulatory milestones with two key pipeline assets, securing approvals to advance clinical development programs in both China and the United States. The company's wholly owned subsidiary Zhuhai United (搜索) received implied approval from China's National Medical Products Administration (搜索) for clinical trials of its dupilumab biosimilar injection for atopic dermatitis (搜索), while separately obtaining FDA approval for TUL321 (搜索) capsules under IND number 180385.
Dupilumab Biosimilar Advances in China
The dupilumab biosimilar injection represents United Laboratories (搜索)' entry into the competitive atopic dermatitis (搜索) treatment market. Dupilumab is a fully human immunoglobulin G4 (搜索) monoclonal antibody specifically designed for treating atopic dermatitis, particularly targeting patients with moderate-to-severe disease whose condition remains inadequately controlled by topical therapies or for whom topical treatments are not advisable.
The implied approval from China's National Medical Products Administration (搜索) enables Zhuhai United (搜索) to proceed with clinical trials, marking a crucial step in the biosimilar's development pathway. This regulatory clearance positions the company to compete in the growing atopic dermatitis (搜索) therapeutics market within China.
TUL321 Receives FDA Clearance
United Laboratories (搜索)' TUL321 (搜索) capsules, classified as a Class 1 innovative drug, have received approval from the U.S. Food and Drug Administration for their Investigational New Drug application. The FDA assigned IND number 180385 to the program, allowing the company to initiate clinical studies in the United States.
The company has adopted a dual-market strategy for TUL321 (搜索), simultaneously submitting a clinical trial application in China, which has been accepted for review by Chinese regulatory authorities. This parallel approach demonstrates United Laboratories (搜索)' commitment to global drug development and market access.
Strategic Pipeline Expansion
These regulatory approvals represent United Laboratories (搜索)' broader strategy to diversify its pipeline beyond traditional pharmaceutical offerings. The company's focus on both biosimilar development through its dupilumab program and innovative drug discovery via TUL321 (搜索) reflects a comprehensive approach to addressing unmet medical needs across multiple therapeutic areas.
The dual approvals underscore United Laboratories (搜索)' capability to navigate complex regulatory environments in major pharmaceutical markets, positioning the company for potential future commercialization opportunities pending successful clinical trial outcomes.